New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) Cagrilintide– Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) US$ 27.90 Min. order: 1 piece ★★★★★ 4.5 (57 reviews) Sold : Login>>
CagriSema Weight Loss Injection Results Safety UK Update US$ 26.67 Min. order: 1 piece ★★★★★ 4.5 (273 reviews) Sold : Login>>
BPC 157 Benefits: Heal & Thrive in 2025 US$ 29.18 Min. order: 1 piece ★★★★★ 4.0 (281 reviews) Sold : Login>>
VisualAbstract: Combined cagrilintide and semaglutide for weight management well-tolerated in early clinical trials US$ 21.78 Min. order: 1 piece ★★★★★ 4.9 (103 reviews) Sold : Login>>